Danish Medicines Council recommends Genmab-developed sclerosis drug

On Thursday, the Danish Medicines Council announced that sclerosis drug Kesimpta, which is owned by Novartis but was developed by Genmab, can be used to treat Danes with relapsing remitting multiple sclerosis and high disease activity.
Photo: Jan Dagø/Jyllands-Posten/Ritzau Scanpix
Photo: Jan Dagø/Jyllands-Posten/Ritzau Scanpix
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen and catherine brett

In December, the Danish Medicines Council wasn’t convinced of the therapeutic advantages of Novartis’s sclerosis drug, Kesimpta.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading